Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

Shi, Qingyang; Wang, Yan; Qin, Hao; Vandvik, Per Olav; Guyatt, Gordon; Li, Jing; Chen, Zhe; Xu, Shuo; Shen, Yanjiao; Ge, Long; Sun, Feng; Li, Ling; Yu, Jiajie; Nong, Kailei; Zou, Xinyu; Zhu, Siyi; Wang, Cong; Zhang, Shengzhao; Qiao, Zhi; Jian, Zhongyu; Li, Ya; Zhang, Xinyi; Chen, Kerun; Qu, Fang; Wu, Yuh Lin; He, Yazhou; Tian, Haoming; Li, Sheyu

doi:10.1016/s0140-6736(21)01640-8

Cited by 180 publications

(142 citation statements)

References 39 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…It is known that the actions of the native human GLP-1 are different in reducing food intake and in controlling blood glucose levels in comparison to GLP-1 receptor agonists. Recent findings demonstrated that in overweight or obese adults, GLP-1 receptor agonists and phentermine–topiramate are the best drugs to reduce body weight; of the GLP-1 agonists, semaglutide might be the most effective [ 43 , 44 , 45 , 46 , 47 ]. Figure 3 summarizes the GLP-1 actions.…”

Section: Use Of Glp1mentioning

confidence: 99%

GLP-1a: Going beyond Traditional Use

Laurindo

Barbalho

Guiguer

et al. 2022

IJMS

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The objective of this study was to perform a systematic review on the use of GLP-1 other than in treating diabetes. PubMed, Cochrane, and Embase were searched, and the PRISMA guidelines were followed. Nineteen clinical studies were selected. The results showed that GLP-1 agonists can benefit defined off-medication motor scores in Parkinson’s Disease and improve emotional well-being. In Alzheimer’s disease, GLP-1 analogs can improve the brain’s glucose metabolism by improving glucose transport across the blood–brain barrier. In depression, the analogs can improve quality of life and depression scales. GLP-1 analogs can also have a role in treating chemical dependency, inhibiting dopaminergic release in the brain’s reward centers, decreasing withdrawal effects and relapses. These medications can also improve lipotoxicity by reducing visceral adiposity and decreasing liver fat deposition, reducing insulin resistance and the development of non-alcoholic fatty liver diseases. The adverse effects are primarily gastrointestinal. Therefore, GLP-1 analogs can benefit other conditions besides traditional diabetes and obesity uses.

show abstract

Section: Use Of Glp1mentioning

confidence: 99%

GLP-1a: Going beyond Traditional Use

Laurindo

Barbalho

Guiguer

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Another weight loss drug, the appetite suppressant phentermine-topiramate isn’t licensed in the EU and UK because of safety concerns. A new meta-analysis concludes: “In adults with overweight and obesity, phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective.”4 The study estimated weight reduction with lifestyle modification alone at 3.38% a year, with an additional 11.41% weight reduction when semaglutide is added. However, the researchers found high levels of gastrointestinal side effects, and semaglutide has to be given as a once weekly injection—at a higher dose than for type 2 diabetes.…”

Section: Glp-1 Agonists Weigh-in To Obesity Managementmentioning

confidence: 99%

Tom Nolan's research reviews—20 January 2022

Nolan¹

2022

BMJ

View full text Add to dashboard Cite

“…Fortunately, modern biotechniques and novel polymer materials made a buddle of good examples of long-acting peptides, including GLP-1 receptor agonists, which are among the most effective anti-diabetic and anti-obesity drugs worldwide. 8 , 9 It is now the time for pharmacists to develop a safe preparation of LEAP2 with rigorous validation in preclinical and clinical studies. Another approach to translate LEAP2 into practice is to inhibit the key enzyme of its degradation by identifying small-molecule inhibitors.…”

Section: Main Textmentioning

confidence: 99%